BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 29, 2024
See today's BioWorld
Home
» With Positive INKP-102 Results, InKine Prepares For NDA Filing
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
With Positive INKP-102 Results, InKine Prepares For NDA Filing
Feb. 23, 2005
By
Jennifer Boggs
No Comments
InKine Pharmaceutical Co. Inc. said its pre-colonoscopy bowel-cleansing drug, INKP-102, met or exceeded endpoints in a Phase III trial compared to the company's marketed purgative product, Visicol. (BioWorld Today)
BioWorld